Share on StockTwits

Stock analysts at Jefferies Group initiated coverage on shares of Repligen Corp. (NASDAQ:RGEN) in a report issued on Tuesday, reports. The firm set a “buy” rating and a $17.00 price target on the stock. Jefferies Group’s target price suggests a potential upside of 24.36% from the company’s current price.

Shares of Repligen Corp. (NASDAQ:RGEN) opened at 13.96 on Tuesday. Repligen Corp. has a 52 week low of $7.37 and a 52 week high of $17.26. The stock has a 50-day moving average of $14.43 and a 200-day moving average of $13.12. The company has a market cap of $445.8 million and a P/E ratio of 27.34.

Repligen Corp. (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, March 6th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.04. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $15.88 million. The company’s revenue for the quarter was down 18.1% on a year-over-year basis. Analysts expect that Repligen Corp. will post $0.24 EPS for the current fiscal year.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.